Business · 18/04/2024Updated: 10/17/2026 · 1 min read
FDA Awards Priority Review Voucher to LENMELDY Manufacturer Orchard Therapeutics
Summary
The FDA has awarded a priority review voucher to Orchard Therapeutics, the manufacturer of LENMELDY (atidarsagene autotemcel), a rare pediatric disease product approved on March 18, 2024, under the Federal Food, Drug, and Cosmetic Act.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →